| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1007/S12026-007-0073-4 |
| P698 | PubMed publication ID | 17917071 |
| P50 | author | George J Weiner | Q61983045 |
| P2093 | author name string | George J Weiner | |
| P2860 | cites work | Continuous cultures of fused cells secreting antibody of predefined specificity | Q26776979 |
| Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets | Q28140238 | ||
| Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4 | Q28156255 | ||
| Tumorigenesis and the angiogenic switch | Q29619849 | ||
| Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia | Q30312115 | ||
| CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations | Q33193071 | ||
| CR3: a general purpose adhesion-recognition receptor essential for innate immunity | Q33887451 | ||
| Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex | Q34314489 | ||
| Trastuzumab/chemotherapy combinations in metastatic breast cancer | Q34759244 | ||
| Monoclonal antibody therapeutics and apoptosis | Q35603396 | ||
| Herceptin: mechanisms of action and resistance | Q36386680 | ||
| Principles and use of anti-CTLA4 antibody in human cancer immunotherapy | Q36389992 | ||
| Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma | Q40318856 | ||
| CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells. | Q40383762 | ||
| Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma | Q40562102 | ||
| Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells | Q40614807 | ||
| Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cyt | Q40795750 | ||
| Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications | Q40920376 | ||
| Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. | Q42635839 | ||
| Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia | Q45230545 | ||
| CpG oligodeoxynucleotides enhance FcgammaRI-mediated cross presentation by dendritic cells. | Q47359389 | ||
| Complement activation determines the therapeutic activity of rituximab in vivo. | Q47745204 | ||
| Humanization and characterization of the anti-HLA-DR antibody 1D10. | Q48350859 | ||
| Regulated expression of FcgammaR in human dendritic cells controls cross-presentation of antigen-antibody complexes. | Q53584954 | ||
| In Vivo Pharmacodynamic Effects of Hu1D10 (Remitogen), a Humanized Antibody Reactive Against a Polymorphic Determinant of HLA-DR Expressed on B Cells | Q57373163 | ||
| Phase II Trial of Remitogen™ (Humanized 1D10) Monoclonal Antibody Targeting Class II in Patients with Relapsed Low-Grade or Follicular Lymphoma | Q57376036 | ||
| Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes | Q69614843 | ||
| A clinical trial of anti-idiotype therapy for B cell malignancy | Q69891840 | ||
| Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells | Q73638542 | ||
| Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma | Q74420422 | ||
| CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59 | Q77220551 | ||
| CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help | Q77402954 | ||
| Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene | Q77535970 | ||
| Monoclonal antibody therapy of cancer | Q81189032 | ||
| P433 | issue | 1-3 | |
| P921 | main subject | antibody | Q79460 |
| monoclonal antibody | Q422248 | ||
| P304 | page(s) | 271-278 | |
| P577 | publication date | 2007-01-01 | |
| P1433 | published in | Immunologic Research | Q15754981 |
| P1476 | title | Monoclonal antibody mechanisms of action in cancer | |
| P478 | volume | 39 |
| Q34923734 | An anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells |
| Q37702283 | Anti-GD2 antibody therapy for GD2-expressing tumors |
| Q39000185 | Antibody therapeutics for treating prostate cancer: where are we now and what comes next? |
| Q26852287 | Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells |
| Q33512089 | Aptamers: from bench side research towards patented molecules with therapeutic applications. |
| Q55285633 | Aptamers: novelty tools for cancer biology. |
| Q39958332 | Cancer immunotherapy. |
| Q37735615 | Cetuximab strongly enhances immune cell infiltration into liver metastatic sites in colorectal cancer |
| Q34623949 | Cetuximab: a review of its use in squamous cell carcinoma of the head and neck |
| Q37890208 | Changing pathology with changing drugs: tumors of the gastrointestinal tract |
| Q33667675 | Characterization of single chain antibody targets through yeast two hybrid |
| Q38563592 | De novo resistance biomarkers to anti-HER2 therapies in HER2-positive breast cancer. |
| Q38198948 | Determining the optimal dose in the development of anticancer agents |
| Q34041344 | Differential Antitumor Effects of IgG and IgM Monoclonal Antibodies and Their Synthetic Complementarity-Determining Regions Directed to New Targets of B16F10-Nex2 Melanoma Cells |
| Q34033964 | Epithelial Membrane Protein-2 Is a Novel Therapeutic Target in Ovarian Cancer |
| Q42218820 | FcγR and EGFR polymorphisms as predictive markers of cetuximab efficacy in metastatic colorectal cancer |
| Q54630456 | FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer |
| Q33763294 | Fusogenics: a recombinant immunotoxin-based screening platform to select internalizing tumor-specific antibody fragments |
| Q53387904 | Genetic polymorphisms of FcγRIIa and FcγRIIIa are not predictive of clinical outcomes after cetuximab plus irinotecan chemotherapy in patients with metastatic colorectal cancer. |
| Q46174844 | Glycosylation of MUC1 influences the binding of a therapeutic antibody by altering the conformational equilibrium of the antigen |
| Q33574029 | ING proteins as potential anticancer drug targets |
| Q38982777 | IgG1 anti-epidermal growth factor receptor antibodies induce CD8-dependent antitumor activity |
| Q37670024 | Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander". |
| Q37431356 | Immune therapies for neuroblastoma |
| Q82004933 | Immunoglobulin E antibodies from pancreatic cancer patients mediate antibody-dependent cell-mediated cytotoxicity against pancreatic cancer cells |
| Q34181954 | Immunological treatment options for locoregionally advanced head and neck squamous cell carcinoma |
| Q36961007 | Immunology at the University of Iowa |
| Q37393024 | Immunotherapy of head and neck cancer using tumor antigen-specific monoclonal antibodies |
| Q37602294 | Impact of molecular markers on treatment selection in advanced colorectal cancer |
| Q64072797 | Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy |
| Q55527185 | New therapeutic options opened by the molecular classification of gastric cancer. |
| Q38178775 | Oncogenes in non-small-cell lung cancer: emerging connections and novel therapeutic dynamics |
| Q34083752 | Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer |
| Q47579371 | Preparation and biological activities of anti-HER2 monoclonal antibodies with fully core-fucosylated homogeneous bi-antennary complex-type glycans |
| Q33621891 | Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients |
| Q37964490 | Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical application. |
| Q35785499 | Reprogramming urokinase into an antibody-recruiting anticancer agent |
| Q89940707 | Site-specific C-terminal dinitrophenylation to reconstitute the antibody Fc functions for nanobodies |
| Q40129971 | The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab. |
| Q37542947 | The role of caveolin-1 in prostate cancer: clinical implications. |
| Q49719408 | The significance of tumor-infiltrating lymphocytes before and after neoadjuvant therapy for rectal cancer. |
| Q58804941 | Typical and Atypical Inducers of Lysosomal Cell Death: A Promising Anticancer Strategy |
Search more.